Skip to main content

Segundo Bujan Rivas

Institutions of which they are part

Systemic Diseases
Vall Hebron Institut de Recerca

Segundo Bujan Rivas

Institutions of which they are part

Systemic Diseases
Vall Hebron Institut de Recerca

Projects

Ajuts Grups de Recerca (SGR) 2022

IP: Jaume Alijotas Reig
Collaborators: Moisés Labrador Horrillo, Carmen Pilar Simeón i Aznar, Anna Sala Cunill, Roser Solans Laque, Segundo Bujan Rivas, Mar Guilarte Clavero, Vicenç Fonollosa Pla, Fernando Martínez Valle, Victòria Cardona Dahl, Francesc Miro Mur, Alfredo Guillen Del Castillo, Albert Selva O'Callaghan, José Pardos Gea, Laura Donaire Lancharro, Ariadna Anunciacion Llunell
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00048
Duration: 01/01/2022 - 30/06/2025

Autoimmunitat i Malaltia Trombòtica (GRC)

IP: Miguel Vilardell Tarres
Collaborators: Carmen Pilar Simeón i Aznar, Roser Solans Laque, Segundo Bujan Rivas, Vicenç Fonollosa Pla, José Ordi Ros, Josefina Cortes Hernandez, Fernando Martínez Valle, Albert Selva O'Callaghan, Cristina Solé Marce
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2014 SGR 329
Duration: 01/01/2014 - 31/12/2016

Autoimmunitat i malaltia trombòtica

IP: Miguel Vilardell Tarres
Collaborators: Carmen Pilar Simeón i Aznar, Ernesto Trallero Araguas, Roser Solans Laque, Segundo Bujan Rivas, Vicenç Fonollosa Pla, José Ordi Ros, Josefina Cortes Hernandez, Fernando Martínez Valle, Jesus Castro Marrero, Albert Selva O'Callaghan
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 49920
Reference: 2009 SGR 661
Duration: 01/01/2010 - 30/04/2014

Estudio de las vías IFN-gamma/STAT y TGF-beta/Smad en pacientes de lupus con afectación cutánea. Papel en la evolución a fibrosis

IP: Miguel Vilardell Tarres
Collaborators: Segundo Bujan Rivas, Vicente García-Patos Briones, Maria Urquizu Padilla
Funding agency: Instituto de Salud Carlos III
Funding: 49980
Reference: PI050249
Duration: 01/01/2006 - 31/12/2008

Related news

The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.

Related professionals

Silvia Serres Soler

Silvia Serres Soler

Tècnic/a Grau Superior
Unitat legal
Legal Directorate
Read more
Magda Jablonska

Magda Jablonska

Postdoctoral researcher
Stroke research
Read more
Ali Haidar

Ali Haidar

Administration and Management
Childhood Cancer and Blood Disorders
Read more
Mariel Rojas Lora

Mariel Rojas Lora

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.